Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
MolBridge: Atom-Level Joint Graph Refinement for Robust Drug-Drug Interaction Event Prediction
arXiv:2510.20448v2 Announce Type: replace-cross Abstract: Drug combinations offer therapeutic benefits but also carry the risk of adverse drug-drug interactions (DDIs), especially under complex molecular structures. Accurate DDI event prediction requires capturing fine-grained inter-drug relationships, which are critical for modeling metabolic mechanisms such as enzyme-mediated competition. However, existing approaches typically rely on isolated drug representations and fail to explicitly model
-
cs.AI, q-bio.NC updates on arXiv.org
-
MolBridge: Atom-Level Joint Graph Refinement for Robust Drug-Drug Interaction Event Prediction
arXiv:2510.20448v1 Announce Type: cross Abstract: Drug combinations offer therapeutic benefits but also carry the risk of adverse drug-drug interactions (DDIs), especially under complex molecular structures. Accurate DDI event prediction requires capturing fine-grained inter-drug relationships, which are critical for modeling metabolic mechanisms such as enzyme-mediated competition. However, existing approaches typically rely on isolated drug representations and fail to explicitly model atom-le
MolBridge: Atom-Level Joint Graph Refinement for Robust Drug-Drug Interaction Event Prediction
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
LcProt: Proteomics-based identification of plasma biomarkers for lung cancer multievent, a multicentre study
Clin Transl Med. 2025 Jan;15(1):e70160. doi: 10.1002/ctm2.70160.ABSTRACTBACKGROUND: Plasma protein has gained prominence in the non-invasive predicting of lung cancer. We utilised Zeolite Zotero NaY-based plasma proteomics to investigate its potential for multiple event predicting, including lung cancer diagnosis (task #1), lymph node metastasis detection (task #2) and tumour‒node‒metastasis (TNM) staging (task #3).METHODS: A total of 4703 plasma proteins were quantified from 241 participants ba
LcProt: Proteomics-based identification of plasma biomarkers for lung cancer multievent, a multicentre study
Clin Transl Med. 2025 Jan;15(1):e70160. doi: 10.1002/ctm2.70160.
ABSTRACT
BACKGROUND: Plasma protein has gained prominence in the non-invasive predicting of lung cancer. We utilised Zeolite Zotero NaY-based plasma proteomics to investigate its potential for multiple event predicting, including lung cancer diagnosis (task #1), lymph node metastasis detection (task #2) and tumour‒node‒metastasis (TNM) staging (task #3).
METHODS: A total of 4703 plasma proteins were quantified from 241 participants based on a prospective cohort of 2757 participants. An additional 46 participants from external prospective cohort of 735 participants were used for validation. Feature selection was performed using differential expressed protein analysis, area under curve (AUC) evaluation and least absolute shrinkage and selection operator (LASSO) regression. Random forest was used for multitask model construction based on the key proteins. Feature importance was interpreted using Shapley additive explanations (SHAP) algorithm.
RESULTS: For task #1, 10 proteins panel showed an AUC of .87 (.77‒.97) in the external validation. After integrating clinical factors, a significant increase diagnostic accuracy was observed with AUC of .91 (.85‒.98). For task #2, nine proteins panel achieved an AUC of .88 (.80‒.96), integration model showed an increase diagnostic accuracy with AUC of .90 (.85‒.97). For task #3, 10 proteins panel showed an AUC of .88 (.74‒.96) for stage I, .92 (.84‒.97) for stage II, .88 (.76‒.96) for stage III and .99 (.98‒.99) for stage IV in the integration model.
CONCLUSIONS: This study comprehensively profiled the NaY-based plasma proteome biomarker, laying the foundation for a high-performance blood test for predicting multiple events in lung cancer.
KEY POINTS: Our study developed an innovative nanomaterial, Zeolite NaY, which addressed the masking effect and improved the depth of the proteome. The performance of NaY-based plasma proteomics as a preclinical diagnostic tool was validated through both internal and external cohort. Furthermore, we explored the different patterns of plasma protein changes during the progression of lung cancer and used the explanations method to elucidate the roles of proteins in the multitask predictive model.
PMID:39783847 | PMC:PMC11714244 | DOI:10.1002/ctm2.70160